High-throughput engineered tumor organoids reveal ROCK signaling as an immunotherapeutic target in triple-negative breast cancer
{{output}}
Triple-negative breast cancer (TNBC) remains resistant to immunotherapy because of its profoundly immunosuppressive tumor microenvironment. Here, we establish a droplet-engineered organoid (DEO) platform that preserves endogenous TILs and supports rapid, immun... ...
